Day One Biopharmaceuticals, Inc.DAWNNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank83
3Y CAGR+22.4%
5Y CAGR+81.5%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+22.4%/yr
Annual compound
5Y CAGR
+81.5%/yr
Recent deceleration
Percentile
P83
Within normal range
vs 5Y Ago
19.7x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$268.72M-21.7%
2024$343.15M+66.8%
2023$205.68M+40.5%
2022$146.38M+101.8%
2021$72.54M+432.4%
2020$13.63M-8.6%
2019$14.90M-